Arca
Skip to content
Tools
Tools

FCGR3A: Low affinity immunoglobulin gamma Fc region receptor III-A

Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG).

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on FCGR3A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2

Approved0

    Phase 31

    • Bemarituzumab

    Phase 21

    • Imgatuzumab

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      BemarituzumabPhase 3Chia Tai Tianqing PharmaceuticalAntibodyBinding agentLow affinity immunoglobulin gamma Fc region receptor III-A binding agent4
      ImgatuzumabPhase 2RocheAntibodyCross-linking agentLow affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
      SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaBemarituzumabPhase 2Not yet recruitingFujian Cancer HospitalMar 13, 2026
      Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in ChildrenBemarituzumab—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyJun 13, 2025
      Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative TreatmentBemarituzumabPhase 1Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTCMay 18, 2025
      A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaBemarituzumabPhase 2RecruitingChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Jan 10, 2025

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity0.69
      • Gastric neoplasm0.33
      • Neoplasm0.13
      • Gastric adenocarcinoma0.10
      • Cancer0.10
      • Posterior cortical atrophy0.10

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3856162, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P08637, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.